Zander R, Cui W. Exhausted CD8(+) T cells face a developmental fork in the road. Trends Immunol. 2023;44:276–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-Checkpoint Restrains T-cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685–700.e8.

Article  CAS  PubMed  Google Scholar 

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386:24–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023;2:EVIDoa2200239.

Article  PubMed  Google Scholar 

Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T-cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell. 2024;187:4355–72.e22.

Article  CAS  PubMed  Google Scholar 

Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to coexpression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell. 2024;187:4373–88.e15.

Article  CAS  PubMed  Google Scholar 

Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, et al. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T-cell NK receptor expression and cytotoxicity. Cell. 2024;187:4336–54.e19.

Article  CAS  PubMed  Google Scholar 

Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving coreceptor-Lck dissociation. Nat Immunol. 2022;23:757–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4(+) T-Cell Help Is Required for the Formation of a Cytolytic CD8(+) T-Cell Subset that Protects against Chronic Infection and Cancer. Immunity. 2019;51:1028–42.e4.

Article  CAS  PubMed  PubMed Central  Google Scholar